{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:45:06Z","timestamp":1771267506805,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.msard.2020.101963","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:53:13Z","timestamp":1579521193000},"page":"101963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5753-6752","authenticated-orcid":false,"given":"E.","family":"Signoriello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"S.","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sinisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.V.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-9939","authenticated-orcid":false,"given":"G.T.","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Casertano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-6317","authenticated-orcid":false,"given":"F.","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-8180","authenticated-orcid":false,"given":"R.","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Brescia","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.101963_bib0001","first-page":"791","article-title":"Recommendations for the use of live attenuated varicella vaccine","volume":"95","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.msard.2020.101963_bib0002","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/338959","article-title":"Persistence of immunity to live attenuated varicella vaccine in healthy adults","volume":"34","author":"Ampofo","year":"2002","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.msard.2020.101963_bib0003","first-page":"361","article-title":"Varicella zoster virus","author":"Ann.","year":"1996","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.msard.2020.101963_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.101963_bib0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.msard.2013.03.002","article-title":"Varicella vaccination after fingolimod: a case report","volume":"2","author":"Berger","year":"2013","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2020.101963_bib0007","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2020.101963_bib0008","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-Week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2020.101963_bib0009","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ni1083","article-title":"Sphingosine 1-phosphate receptor 1 promotes b cell localization in the splenic marginal zone","volume":"5","author":"Cinamon","year":"2004","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2020.101963_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-Month follow-up study","volume":"9","author":"Claes","year":"2014","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.msard.2020.101963_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.msard.2020.101963_bib0012","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/infdis\/161.4.661","article-title":"Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. national institute of allergy and infectious diseases varicella vaccine collaborative study group","volume":"161","author":"Gershon","year":"1990","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.101963_bib0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"FTY720 in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2020.101963_bib0014","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1542\/peds.100.5.761","article-title":"A long-term prospective study of varicella vaccine in healthy children","volume":"100","author":"Johnson","year":"1997","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.msard.2020.101963_bib0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101963_bib0016","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.101963_bib0017","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ene.12132","article-title":"Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"20","author":"Kim","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.101963_bib0018","series-title":"Neurology: A Queen Square Textbook","first-page":"411","article-title":"Multiple sclerosis and demyelinating diseases","author":"Leary","year":"2009"},{"key":"10.1016\/j.msard.2020.101963_bib0019","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1212\/01.wnl.0000188901.12700.e0","article-title":"Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a","volume":"65","author":"Lopez-Bresnahan M","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.101963_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jnnp-2013-305450","article-title":"Incidence and prevalence of multiple sclerosis in the uk 1990\u20132010: a descriptive study in the general practice research database","volume":"85","author":"Mackenzie","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2020.101963_bib0021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.101963_bib0022","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/S0264-410X(00)00016-5","article-title":"Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects: 10-year survey at pediatric clinic","volume":"18","author":"Ozaki","year":"2000","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.msard.2020.101963_bib0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ane.12357","article-title":"Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome","volume":"131","author":"Signoriello","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2020.101963_bib0024","unstructured":"US Food and Drug Administration. Gilenya (fingolimod) prescribing information. 2016. Available from:http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf. Accessed 25 May 2016."},{"key":"10.1016\/j.msard.2020.101963_bib0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/169.1.197","article-title":"Persistence of cell mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine","volume":"169","author":"Watson","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.101963_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","article-title":"Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response","volume":"11","author":"White","year":"1992","journal-title":"Pediatr Infect Dis J"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:54Z","timestamp":1761900594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820300390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":25,"alternative-id":["S2211034820300390"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.101963","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.101963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101963"}}